Which of the following is an FDA label indication for Fluconazole?

Fluconazole is primarily indicated for the treatment of systemic candidiasis, which refers to a serious fungal infection that can occur in various parts of the body, often affecting immunocompromised individuals. This antifungal medication works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes, thus helping to combat infections caused by Candida species.

In contrast, options related to acne vulgaris, HIV/AIDS treatment, and chronic pain do not align with the established uses of Fluconazole. Acne vulgaris is typically treated with topical retinoids or systemic antibiotics, while HIV/AIDS is managed with antiretroviral therapies specifically designed to suppress the viral load. Chronic pain requires analgesics or other pain management strategies rather than an antifungal agent like Fluconazole. Therefore, the correct choice highlights the specific FDA-approved use of Fluconazole in addressing systemic candidiasis infections.